ANRO · US market
Alto Neuroscience Inc
Compare this company’s P/E and P/S using trailing results and the latest quarter. Ratios are calculated here from market capitalisation, signed ordinary or common-shareholder earnings and revenue.
Market cap US$993.22mFinancials dated 30 June 2026Price dated 1 October 2026
Core valuation
Calculation inputs
- Trailing earnings
- -US$84.24m
- Latest-quarter run-rate earnings
- -US$110.55m
- Latest fiscal-year earnings
- -US$63.24m
- Trailing revenue
- US$0.00
- Latest-quarter run-rate revenue
- US$0.00
- Latest fiscal-year revenue
- Unavailable
Featured ETF and mutual-fund exposure
These public funds report this company in their latest disclosed holdings.
- XPH · State Street SPDR S&P Pharmaceuticals ETF1.41% weight · Holdings dated 21 August 2026
- IBRN · iShares Neuroscience and Healthcare ETF1.07% weight · Holdings dated 21 August 2026
- IWC · iShares Micro-Cap ETF0.20% weight · Holdings dated 21 August 2026
- IBB · iShares Biotechnology ETF0.08% weight · Holdings dated 19 August 2026
- VFMO · Vanguard U.S. Momentum Factor ETF0.08% weight · Holdings dated 15 September 2026
- VTWG · Vanguard Russell 2000 Growth ETF0.06% weight · Holdings dated 31 August 2026
- IWO · iShares Russell 2000 Growth ETF0.05% weight · Holdings dated 19 August 2026
- VTWO · Vanguard Russell 2000 ETF0.03% weight · Holdings dated 31 August 2026
- IWM · iShares Russell 2000 ETF0.03% weight · Holdings dated 19 August 2026
- DTSGX · Wilshire Small Company Growth Portfolio Investment Class Shares0.02% weight · Holdings dated 30 June 2026
Sources and limitations
Financial inputs are attributed to SEC EDGAR. Market cap is calculated locally where auditable price and share inputs are available. Missing data stays missing; losses are retained as signed values and produce a numeric signed P/E.
Open financial sourceFinancials as of 30 June 2026. Informational research, not investment advice.